Elanco launches Befrena for dogs with allergic and atopic dermatitis

Elanco is expanding its canine dermatology lineup with the phased U.S. launch of Befrena (tirnovetmab), a USDA-approved anti-IL-31 monoclonal antibody injection for dogs with allergic and atopic dermatitis. The company said May 18, 2026, that Befrena is now entering the market after receiving USDA approval in December 2025, adding a second recent dermatology product to Elanco’s portfolio alongside Zenrelia. Elanco positions Befrena as an in-clinic injectable that begins controlling itch within 24 hours and is typically dosed every 6 to 8 weeks. (prnewswire.com)

Why it matters: For veterinary professionals, Befrena adds another biologic option in a category where chronic itch remains one of the most common reasons dogs present for care. Because it targets IL-31 rather than broadly suppressing the immune system, the product may appeal to clinicians looking for another targeted therapy for allergic pruritus, especially for patients needing an injectable option, longer intervals between visits, or multimodal management. Elanco’s veterinary materials say Befrena was well tolerated in studies, can be used alongside a range of concomitant medications, and has shown efficacy for up to 8 weeks, though clinicians will still need to weigh individual response, cost, scheduling, and the practical realities of monitoring flare-ups between doses. (my.elanco.com)

What to watch: Watch for broader clinic uptake, real-world comparisons with existing IL-31 biologics, and whether Elanco releases peer-reviewed data or additional field experience as the phased launch continues. (prnewswire.com)